Table 2.
Plasma palbociclib steady‐state pharmacokinetics in a subset of 6 Japanese postmenopausal patients with ER+/HER2− ABC receiving palbociclib plus letrozole
| Summary statisticsa | |
|---|---|
| Parameter (units) | Palbociclib + Letrozole Cycle 1/Day 15 n = 6 |
| AUCτ (ng·h/mL) | 1979 (16) |
| Cmax (ng/mL) | 124.7 (26) |
| tmax (h) | 4.90 (2.00‐8.20) |
| CL/F (L/h) | 63.2 (16) |
ABC, advanced breast cancer; AUCτ, area under the plasma concentration‐time curve over dosing interval τ using the linear/log trapezoidal method; CL/F, apparent clearance determined by dose/AUCτ; Cmax, maximum plasma concentration observed directly from the data; ER+, estrogen receptor‐positive; HER2−, human epidermal growth factor receptor 2‐negative; tmax, time to Cmax observed directly from the data as time of first occurrence.
a
Data are geometric mean (geometric % coefficient of variation) except for median tmax (median [range]).